Story

Excellamol’s proprietary extracellular matrix technology was developed by Dr. Won Bae Jeon in the Laboratory of Biochemistry and Cellular Engineering at DGIST. Dr. Jeon’s laboratory focuses on producing recombinant matrix proteins that address unmet clinical needs for targeted delivery of anticancer drugs and stem cells.

Extensive mechanistic investigations through cellular and animal studies, coupled with an exclusive patent portfolio, have successfully positioned Excellamol to develop its own original pharmaceutical products for cancer treatment.

Mission

Develop first-in-class polypeptide-drug conjugates for the treatment of brain and pancreatic cancers.

Leadership